Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:


Exploiting KRAS-mediated metabolic reprogramming as a therapeutic target

Half of all colorectal cancers bear KRAS-activating mutations that affect the metabolic dependencies of cancer cells and drive resistance to commonly used drugs. A new study provides insights into KRAS-driven metabolic rewiring and identifies a new therapeutic target for KRAS-mutant cancers.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Loss of Slc7a5 attenuates Kras-driven tumor progression.


  1. Fearon, E. R. & Vogelstein, B. Cell 61, 759–767 (1990).

    Article  CAS  Google Scholar 

  2. The Cancer Genome Atlas Network. Nature 487, 330–337 (2012).

    Article  Google Scholar 

  3. Schwitalla, S. et al. Cell 152, 25–38 (2013).

    Article  CAS  Google Scholar 

  4. Haigis, K. M. et al. Nat. Genet. 40, 600–608 (2008).

    Article  CAS  Google Scholar 

  5. Verissimo, C. S. et al. eLife 5, e18489 (2016).

    Article  Google Scholar 

  6. Gimple, R. C. & Wang, X. Front. Oncol. 9, 965 (2019).

    Article  Google Scholar 

  7. Kimmelman, A. C. Clin. Cancer Res. 21, 1828–1834 (2015).

    Article  CAS  Google Scholar 

  8. Warburg, O. Science 123, 309–314 (1956).

    Article  CAS  Google Scholar 

  9. Smith, B. et al. Cell Rep. 17, 821–836 (2016).

    Article  CAS  Google Scholar 

  10. Ying, H. et al. Cell 149, 656–670 (2012).

    Article  CAS  Google Scholar 

  11. Najumudeen, A. K. et al. Nat. Genet. (2020).

  12. Guinney, J. et al. Nat. Med. 21, 1350–1356 (2015).

    Article  CAS  Google Scholar 

  13. Canon, J. et al. Nature 575, 217–223 (2019).

    Article  CAS  Google Scholar 

  14. Hallin, J. et al. Cancer Discov. 10, 54–71 (2020).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations


Corresponding author

Correspondence to Louis Vermeulen.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bootsma, S., van Neerven, S.M. & Vermeulen, L. Exploiting KRAS-mediated metabolic reprogramming as a therapeutic target. Nat Genet 53, 9–10 (2021).

Download citation

  • Published:

  • Issue Date:

  • DOI:


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing